🔗 Share this article

The first new treatments for gonorrhoea in many years are being described as a "significant breakthrough" in the effort against superbug strains of the infection, according to researchers.

A Worldwide Health Concern

Gonorrhoea infections are on the rise globally, with data suggesting more than 82 million instances per year. Notably increased rates are seen in the African continent and countries within the World Health Organization's Western Pacific region, which spans from Mongolia and China to New Zealand. In England, cases have hit a record high, while rates across Europe in 2023 were triple the level compared to figures for 2014.

“The approval of fresh medications for gonorrhoea is an important and timely development in the face of rising global incidence, escalating drug resistance and the highly restricted available drugs presently on offer.”

Health officials are increasingly worried about the surge in antibiotic-resistant strains. The WHO has designated it as a "priority pathogen". Recent surveillance found that resistance to primary antibiotics like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Treatment Options Gain Approval

One new antibiotic, marketed under the name Nuzolvence, was cleared by the American regulatory agency in recent days for use against gonorrhoea. This infection can lead to serious health problems, including the inability to conceive. Researchers hope that focused deployment of this new drug will help slow the spread of drug resistance.

Another new antibiotic, created by the pharmaceutical company GSK, also received approval in concurrent days. This drug, which is also used to treat UTIs, was proven in research to be effective against superbug versions of the gonorrhoea bacteria.

A Unique Development Model

Zoliflodacin was the result of a unique collaborative effort for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the drug firm Innoviva to see it through.

“This authorization represents a huge turning point in the therapy of highly resistant gonorrhoea, which previously has been evolving faster than antibiotic development.”

Clinical Trial Data and Worldwide Availability

According to findings detailed in a prominent scientific publication, the new drug successfully treated the vast majority of cases of the STI. This puts it on an equal footing with the current standard treatment, which uses a dual-drug approach. The research included hundreds of participants from multiple nations including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its development partnership, the non-profit has the ability to make available and distribute the drug in many developing nations.

Doctors treating patients have voiced hope. The availability of a single-dose, oral treatment of this kind is hailed as a "critical tool" for managing the epidemic. This is deemed crucial to lessen the impact of the disease for individuals and to halt the transmission of untreatable gonorrhoea around the world.